Clinical reviews in allergy & immunology · 2026
Mesenchymal Stem/Stromal Cells and Their Derived Extracellular Vesicles: a Promising Therapeutic Strategy for Autoimmune Hepatitis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdelgawad Mai, Allam Sahar, Javed Amaan, Law Jia Xian, Tan Shing Cheng
Аннотация
Autoimmune hepatitis (AIH) is an idiopathic autoimmune disorder characterized by chronic liver inflammation that, if untreated, can lead to liver fibrosis and cirrhosis, hepatic failure, and death. Current treatment options for this potentially life-threatening disorder include either high-dose immunosuppressants or liver transplantation (for late-stage patients). However, these options are risky and can lead to long-term complications. Therefore, there is an urgent need to develop novel treatment strategies for AIH. Therapeutic approaches based on mesenchymal stem/stromal cells (MSCs) and their derived extracellular vesicles (EVs) have emerged as a viable treatment option for AIH because of their potent immunomodulatory and anti-inflammatory properties. This review outlines the recent developments in the use of these therapies for the treatment of AIH. The use of EVs as vehicles for the delivery of therapeutic drugs or miRNAs is also discussed. In addition, we discuss the various efforts that have been made to improve the efficacy of such therapies, including their genetic modification and combination with anti-inflammatory drugs. Finally, we proposed several directions for future research aimed at developing MSCs and MSC-derived EVs for clinical applications.